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Abstract
Neuroblastoma is a pediatric malignancy characterized by tremendous clinical heterogeneity, in which some
tumors are extremely aggressive while others spontaneously differentiate into benign forms. Because the degree of
differentiation correlates with prognosis, and because differentiating agents such as retinoic acid (RA) have proven
to decrease mortality, much effort has been devoted to identifying critical regulators of neuroblastoma differentia-
tion in the cellular microenvironment, including cues encoded in the extracellular matrix (ECM). While signaling
between tumor cells and the ECM is classically regarded to be based purely on biochemical recognition of ECM
ligands by specific cellular receptors, a number of recent studies have made it increasingly clear that the biophysi-
cal properties of the ECM may also play an important role in this cross-talk. Given that RA-mediated neuroblastoma
differentiation is accompanied by profound changes in cell morphology and neurite extension, both of which pre-
sumably rely upon mechanotransductive signaling systems, it occurred to us that mechanical cues from the ECM
might also influence RA-mediated differentiation, which in turn might regulate clinically-relevant aspects of neuro-
blastoma biology. In this study, we tested this hypothesis by subjecting a series of neuroblastoma culture models
to ECM microenvironments of varying mechanical stiffness and examined the regulatory role of ECM stiffness in
proliferation, differentiation, and expression of tumor markers. We find that increasing ECM stiffness enhances neur-
itogenesis and suppresses cell proliferation. Remarkably, increasing ECM stiffness also reduces expression of N-Myc,
a transcription factor involved in multiple aspects of oncogenic proliferation that is used for evaluating prognosis
and clinical grading of neuroblastoma. Furthermore, the addition of RA enhances all of these effects for all ECM
stiffnesses tested. Together, our data strongly support the notion that the mechanical signals from the cellular
microenvironment influence neuroblastoma differentiation and do so synergistically with RA. These observations
support further investigation of the role of microenvironmental mechanical signals in neuroblastoma proliferation
and differentiation and suggest that pharmacological agents that modulate the underlying mechanotransductive
signaling pathways may have a role in neuroblastoma therapy.
Findings
Inducing tumor cells to differentiate is an important
therapeutic goal in cancer, especially in neuroblastoma,
one of the few malignancies that demonstrates sponta-
neous differentiation and regression to a benign state
[1]. Previous research has shown that cross-talk between
neuroblastoma cells and the extracellular matrix (ECM)
influences differentiation [2], and recent studies have
identified key genes that regulate those interactions
[3,4]. Neuroblastoma differentiation can also be induced
pharmacologically with retinoic acid (RA) [5]; indeed,
RA has been demonstrated to have significant clinical
benefit in neuroblastoma, which has resulted in inclu-
sion of RA in treatment regimens for high risk disease
[6-8]. RA-induced signaling in neuroblastoma affects
expression of N-Myc and other proto-oncogenes but
also has been shown to alter the expression and activity
of integrins, Rho GTPases, and the actin cytoskeleton.
These molecular components act in concert to sense
a n dp r o c e s ss i g n a l sf r o mt h eE C M[ 9 - 1 2 ]a n dt om e d -
iate cell shape and cytoarchitecture. In addition, altering
the biochemical composition of the ECM itself induces
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[13-15]. Together, these data strongly hint that signals
encoded in the ECM may play a significant role in guid-
ing NB differentiation.
While the ECM is classically regarded to instruct cell
behavior primarily through biochemical recognition by
cell adhesion receptors, it has become increasingly clear
that another component of ECM-based signaling is fun-
damentally biophysical in nature. In particular, the
mechanical rigidity (stiffness) of the ECM can pro-
foundly alter cellular behavior, including morphology,
motility, and proliferation [16-18]. While the mechan-
isms of this “rigidity sensing” remain incompletely
understood, ECM rigidity appears to dictate the amount
of stress or strain the cellular cytoskeleton can impose
upon adhesion plaques, which is then sensed by specific
mechanosensory molecules and regulates both adhesion
plaque maturation and adhesion-dependent signaling
[19-21]. In fact, many processes relevant to neuroblas-
toma, such as stem cell differentiation, neuronal matura-
tion, neurite extension, and the malignant potential and
phenotype of tumor cells have all been shown to be
influenced by ECM stiffness and other biophysical prop-
erties [19,22-30]. Interestingly, signaling pathways that
underlie this biophysical cross-talk and those implicated
in RA-mediated neuritogenesis partially coincide
[16,31-34], suggesting that mechanotransductive signals
from the ECM may affect neuroblastoma differentiation.
In this study, we tested the hypothesis that mechanical
cues from the ECM might influence spontaneous and
RA-induced neuroblastoma differentiation and the
expression of clinically-relevant markers of cell prolifera-
tion and differentiation. We cultured neuroblastoma
cells on ECM substrates of various stiffnesses, exposed
the cells to defined doses of RA, and measured neurite
extension and Ki67 and N-Myc expression. To control
ECM stiffness, we fabricated polyacylamide (PA) hydro-
gels whose stiffness could be controlled by setting the
monomer (acrylamide): crosslinker (bis-acrylamide) ratio
and which could be rendered suitable for cell adhesion
by covalently conjugating collagen I. We and others
have previously validated this platform [35,36] and
demonstrated that ECM rigidity can be varied indepen-
dently of biochemical composition and ligand density
[29,37,38].
To investigate how ECM rigidity affects morphological
differentiation, we cultured SK-N-DZ neuroblastoma
cells on collagen I-laminated PA gels of varying rigid-
ities. The stiffnesses of our ECMs overlapped the range
of bulk rigidities of in vivo tissues, including tissues of
origin and metastasis for neuroblastoma (0.01 kPa to
10000 kPa) [39]. Cells exhibited dramatic stiffness-
dependent phenotypic differences, with cells cultured on
stiffer ECMs coalescing into a few large clusters with
extensive actin-rich neurites, which are hallmarks of
neuroblastoma differentiation [40]. In contrast, cells cul-
tured on softer ECMs were more homogenously dis-
persed and exhibited less clustering and neuritogenesis.
The addition of 13-cis-RA increased neuritogenesis
under all conditions (Figure 1A). Neurite length is used
as a morphological index of the extent of neuroblastoma
differentiation [9,12,41], and indeed, the average neurite
length per cell cluster increased with increasing ECM
rigidity (Figure 1B). However, this relationship was not
linear across the range of ECM rigidities, as neurite
lengths of cells cultured on ECMs with rigidities of 0.01
and 0.1 kPa were statistically indistinguishable from
each other but statistically different compared to other
groups (p < 0.01). Similarly, neurite lengths of cells on
ECMs with rigidities from 50 to 10,000 kPa were not
statistically different from each other but were statisti-
cally different compared to the other groups (p < 0.01).
Within the range of ECM rigidities we tested, we
observed three regimes of neurite lengths at 0.01-0.1
kPa, 1 kPa, and 50-10000 kPa that were statistically dis-
tinct from one another. Furthermore, we found that the
addition of RA increased neurite length for all rigidities
tested and that this increase was independent of sub-
strate stiffness. We observed similar trends with SH-
SY5Y and SK-N-SH cell lines, suggesting that this effect
is generalizable across multiple neuroblastoma models
(Additional file 1).
To rule out the possibility that ECM stiffness-dependent
differences in neurite lengths were solely due to biome-
chanical facilitation of neurite extension rather than
alterations in proliferation and differentiation per se,w e
directly investigated the effect of ECM stiffness on neu-
roblastoma cell proliferation. When we immunostained
SK-N-DZ neuroblastoma cells for the proliferative mar-
ker Ki67, we found that cells cultured on softer ECMs
showed increased Ki67 staining than cells cultured on
stiffer ECMs (Figure 2A). To quantify cell number more
rigorously, we measured metabolic activity with the col-
orimetric mitochondrial reductase substrate WST-1,
which revealed an inverse correlation between ECM
stiffness and cell proliferation either with or without
exposure to RA (r = 0.99 and 0.97, respectively; Figure
2B). Exposure to RA further reduced cell proliferation
on both high and low ECM rigidities, consistent with
our measurements of neurite length.
To explore whether ECM rigidity might also influence
the expression of markers with clinical prognostic value,
we measured the effects of ECM stiffness on the expres-
sion of N-Myc, a key transcription factor involved in
many aspects of cell proliferation. N-Myc gene amplifi-
cation is an important clinical prognostic marker in
neuroblastoma, and reducing N-Myc expression can
induce neuroblastoma differentiation in vitro and may
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tumors [1,42-47]. Quantitative RT-PCR analyses using
the N-Myc-amplified SK-N-DZ cell line revealed that
N-Myc expression decreases with increasing ECM rigid-
ity and that ECM rigidity appears to have a synergistic
effect with RA in reducing N-Myc expression (Figure 3).
Signals from the ECM canonically direct cell behavior
through biochemical recognition by receptors at the cell
surface, which in turn triggers specific signaling net-
works that alter cell behavior. In this study, we show
that mechanical signals encoded in the ECM (i.e., ECM
rigidity) can modulate neuroblastoma cell behaviors
relevant to tumorigenesis. Specifically, we have shown
ECM rigidity potentiates neuroblastoma cell differentia-
tion and decreases cell proliferation and N-Myc expres-
sion. Furthermore, ECM rigidity appears to act
synergistically with RA-induced cell differentiation as
evidenced by morphometric analysis and measurements
of cell proliferation and N-Myc expression. Further stu-
dies are required to elucidate the underlying mechan-
isms of this phenomenon, but the decreased cell
proliferation observed with increasing ECM rigidity may
be due in part to the attenuation of N-Myc expression.
It is also highly likely that components of the cellular
mechanotransductive machinery, such as integrins,
adhesion proteins, Rho family GTPases, and cytoskeletal
proteins are key players, and further study will be
needed to narrow this list. In addition, while our results
show that mechanical inputs can control N-Myc expres-
sion, it remains to be seen whether this relationship is
bidirectional; i.e., whether manipulation of N-Myc
expression can control mechanosensitivity. In addition,
future experiments involving primary human neuroblas-
toma cells should help determine to what extent our
results with culture models are directly translatable to
the clinical disease. While many biochemical and
Figure 1 Extracellular matrix rigidity influences morphological differentiation of neuroblastoma cells. (A) Phase contrast and fluorescence
images of cell nuclei (DAPI) and actin (phalloidin) of SK-N-DZ neuroblastoma cells cultured on 0.1 kPa versus 1000 kPa collagen-coated
polyacrylamide (PA) gels with or without exposure to 1 μM 13-cis RA for three days. Scalebar = 50 μm. (B) Average neurite length of SK-N-DZ
neuroblastoma cell clusters cultured on collagen-coated PA gels of varying rigidities with and without exposure to 1 μM 13-cis RA. Populations
within brackets are statistically indistinguishable from each other but statistically distinguishable from populations in the other brackets (p < 0.01
for all significant comparisons). Each population represents >100 cell clusters. 90th percentile, 75th percentile, median, 25th percentile, and 10th
percentile values are represented by the top whisker, top line, middle line, bottom line, bottom whisker, respectively, of each bar.
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neuroblastoma cell differentiation and sensitivity to che-
motherapeutic agents, to our knowledge this is the first
evidence that a purely biophysical parameter can directly
influence biological indicators of neuroblastoma differ-
entiation that correlate with prognosis and sensitivity to
a pharmacologic agent.
This study raises novel questions about both neuro-
blastoma biology and therapy that warrant further inves-
tigation. For example, RA is insufficient as a single agent
to achieve sustained clinical remission, and our results
raise the intriguing prospect that this may be due in
part to the absence of additional microenvironmental
cues needed to achieve optimal differentiation. In parti-
cular, neuroblastoma metastasizes to a wide variety of
tissues and it is possible that the diversity of mechanical
microenvironments encountered in these tissues might
modulate either malignant phenotype or RA chemosen-
sitivity. Interestingly, additional studies revealed that
ECM rigidity did not affect neuroblastoma chemosensi-
tivity to doxorubicin (Additional File 2), suggesting that
the observed synergy between ECM rigidity and phar-
macological agents may not occur with standard che-
motherapy but only with differentiation agents such as
RA. In addition, our results beg the question of whether
pharmacologic modulation of mechanotrandsductive sig-
naling pathways may have a role in neuroblastoma
Figure 2 Extracellular matrix rigidity modulates neuroblastoma cell proliferation. (A) Phase contrast and fluorescence images of cell nuclei
(DAPI) and Ki67 antibody staining (red), a marker of cell proliferation, of SK-N-DZ neuroblastoma cells on 0.1 kPa and 1000 kPa collagen-coated
PA gels in the presence or absence of 1 μM 13-cis RA for three days. Scalebar = 50 μm. (B) WST-1 cell proliferation assay of SK-N-DZ
neuroblastoma cells cultured on 1, 50, and 300 kPa collagen-coated PA gels with and without exposure to 1 μM 13-cis RA for three days. Error
bars represent standard deviations of 5 technical replicates.
Figure 3 ECM rigidity modulates N-myc expression in
neuroblastoma cells and does so synergistically with retinoic
acid. Quantitative-RT-PCR analysis of relative N-Myc expression in
SK-N-DZ neuroblastoma cells cultured on 1.0 kPa versus 300 kPa
collagen-coated PA gels in the presence or absence of 1 μM 13-cis
RA for three days. Error bars represent standard deviations of 3
technical replicates.
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from the ECM can modulate tumor cell differentiation
has implications beyond neuroblastoma, as N-Myc over-
expression can contribute to the pathophysiology of
other cancers, such as retinoblastoma, small cell lung
carcinoma, and glioblastoma [48].
Materials and methods
Polyacrylamide gels
Polyacrylamide gels of defined rigidity were synthesized
as previously described [29,36].
Cell lines, stains, pharmacological agents
SK-N-DZ, SH-SY5Y, and SK-N-SH cell lines (ATCC)
were cultured on polyacrylamide gels of varying rigid-
ities at 5% CO2, 37°C in DMEM/10% FBS with or with-
out 13-cis-RA (Sigma). Neurite length measurements
were made via direct visualization with phase-contrast
microscopy. Ki67, DAPI, and phalloidin (Invitrogen)
fluorescence staining were performed on cells cultured
on the gels after 2% paraformaldehyde fixation and 0.1%
Triton X (Sigma) permeabilization. For experiments
involving Ki67 staining, microscopy settings (exposure
time, gain, etc.) remained constant to allow for qualita-
tive comparisons in fluorescence signal across different
conditions.
Statistical analyses
Analyses of variances were used to compare measure-
ments of average neurite lengths per cell cluster on sub-
strates of different rigidities (SPSS). Bonferroni post-hoc
analyses were performed to compare each pair of
populations.
RNA extraction and RT-PCR
RNA was extracted from the cells on gels by and con-
verted to DNA using standard Trizol (Invitrogen) and
reverse transcriptase (Applied Biosystems) protocols.
Gene expression via RT-PCR using the ΔΔCt method
was performed using primers for N-myc
(Hs01014940_m1 from Applied Biosystems) and
GAPDH as a control.
WST-1 cell proliferation assay
Cells were seeded at the same cell density for all experi-
ments and cultured on ECMs of varying rigidities. After
three days, WST-1 reagent (Roche) was added to the
medium at 10% final volume and incubated for 2.5 hr.
Supernatant was then analyzed per manufacturer’s
specifications.
Additional file 1: Extracellular matrix rigidity influences
morphological differentiation of SH-SY5Y and SK-N-SH
neuroblastoma cells. (A) Average neurite length of SH-SY5Y
neuroblastoma cell clusters cultured on collagen-coated PA gels of
varying rigidities with and without exposure to 1 μM 13-cis RA. (B)
Average neurite length of SK-N-SH neuroblastoma cell clusters cultured
on collagen-coated PA gels of varying rigidities with and without
exposure to 1 μM 13-cis RA. Populations within brackets are statistically
indistinguishable from each other but statistically distinguishable from
populations outside those brackets (p < 0.05 for all significant
comparisons). Each population represents >100 cell clusters. 90th
percentile, 75th percentile, median, 25th percentile, and 10th percentile
values are represented by the top whisker, top line, middle line, bottom
line, bottom whisker, respectively, of each bar.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-35-
S1.PDF]
Additional file 2: ECM rigidity does not affect neuroblastoma
chemosensitivity to doxorubicin. SK-N-DZ neuroblastoma cells were
cultured on several collagen-coated PA gels with rigidities of 1 and 300
kPa and then exposed to 1 μM doxorubicin. At 24 hr of exposure to
doxorubicin, cells were also exposed to 25 μg/mL of propidium iodide
(PI), a fluorescent marker for cell death, and then immediately detached
from the PA gels and separated using Accutase and Accumax,
respectively (Innovative Cell Technologies). Using flow cytometry, the
proportion of live (PI negative) versus dead cells (PI positive) of each cell
suspension was then determined. The protocol was repeated at 72 hr of
doxorubicin exposure on separate cells cultured on collagen-coated PA
gels with the same rigidities. At both 24 hr (A) and 72 hr (B), there was
no appreciable difference in the proportion of live versus dead cells
between SK-N-DZ neuroblastoma cells cultured on 1 kPa gels versus 300
kPa gels.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-35-
S2.PDF]
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